Isavuconazole for fungal infections in ICU patients
Part of Infections clinical trials.
This study tests how well and how safely the antifungal drug isavuconazole works in critically ill adults in intensive care who have a fungal infection (invasive fungal infection). If you are in the ICU with a suspected or confirmed fungal infection, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are currently in the intensive care unit (ICU) because of a serious illness.
- You have or are suspected to have a fungal infection that has spread inside your body.
- Your infection diagnosis follows specific medical guidelines for invasive fungal infections.
- You are not allergic to isavuconazole or similar drugs.
- You do not have a rare heart condition called inherited short QT syndrome.
- You can take medications by mouth or through a feeding tube.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study monitors how the antifungal drug isavuconazole works in children's bodies. It aims to find the right dose for treating serious fungal infections.
This trial tests whether a medicine called rezafungin can help prevent serious fungal infections in people who have received a liver transplant. If you have certain risk factors, this study may offer extra protection against infections.
This trial aims to personalize the dose of the antifungal drug isavuconazole for adults over 60 with invasive aspergillosis or mucormycosis. By monitoring drug levels in the blood, doctors hope to improve treatment effectiveness and safety specifically for older patients.
This study looks at how two antifungal medicines (anidulafungin and caspofungin) behave in the blood of critically ill ICU patients. It may help doctors better understand which dosing works best when patients have low blood protein levels or fluid leakage.
This trial tests BSG005, a new IV medicine for patients with invasive fungal infections that haven't improved with standard treatment or can't use standard treatments due to side effects or resistance. The goal is to see if it's safe and effective.
This trial tests a combination of antifungal medicines (liposomal amphotericin B and either isavuconazole or posaconazole) for people with blood cancers who develop a fungal infection despite taking preventive antifungal drugs. It aims to find a better treatment for these difficult infections.
Hear when a new Fungal Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.